403 related articles for article (PubMed ID: 9541627)
1. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal.
González Barón M; Feliu J; Ordoñez A; Colmenarejo A; Espinosa E; Zamora P; de la Gandara I; Jalon JI
Anticancer Res; 1993; 13(3):759-62. PubMed ID: 8317909
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
7. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
10. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
Lembersky BC; Wieand HS; Petrelli NJ; O'Connell MJ; Colangelo LH; Smith RE; Seay TE; Giguere JK; Marshall ME; Jacobs AD; Colman LK; Soran A; Yothers G; Wolmark N
J Clin Oncol; 2006 May; 24(13):2059-64. PubMed ID: 16648506
[TBL] [Abstract][Full Text] [Related]
11. [Phase I study of orally administered UFT plus l-leucovorin].
Horikoshi N; Aiba K; Kanamaru R; Hasegawa K; Takeda S; Taguchi T; Niitani H; Furue H; Kurihara M; Ogawa M; Abe T
Gan To Kagaku Ryoho; 1998 Mar; 25(4):531-9. PubMed ID: 9530359
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
Passardi A; Maltoni R; Milandri C; Cecconetto L; Massa I; Zoli W; Tesei A; Fabbri F; Nanni O; Amadori D
Oncology; 2007; 72(1-2):118-24. PubMed ID: 18004083
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of UFT plus leucovorin in colorectal cancer.
Pazdur R
Oncology; 1997; 54 Suppl 1():19-23. PubMed ID: 8978580
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
[TBL] [Abstract][Full Text] [Related]
15. UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
Sastre J; Aranda E; Abad A; Gallego J; Manzano JL; Gómez A; Carrato A; López E; Díaz-Rubio E;
Anticancer Drugs; 2006 Apr; 17(4):417-21. PubMed ID: 16549999
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Pazdur R
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer.
Tedesco KL; Berlin J; Blanke CD; Teng M; Choy H; Roberts J; Beauchamp RD; Leach S; Wyman K; Tarpley J; Shyr Y; Caillouette C; Chakravarthy B
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1364-70. PubMed ID: 15817338
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.
Byström P; Frödin JE; Berglund A; Wilking N; Glimelius B
Radiother Oncol; 2004 Feb; 70(2):171-5. PubMed ID: 15028404
[TBL] [Abstract][Full Text] [Related]
20. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities.
Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
Anticancer Drugs; 1996 Sep; 7(7):728-33. PubMed ID: 8949982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
